Vivimed Labs Limited has secured significant legal relief through an interim stay order from the Telangana High Court, halting all proceedings related to a Central Bureau of Investigation case and preventing State Bank of India from declaring the company's account as fraudulent.

CBI Case Details and Allegations

The Central Bureau of Investigation registered case no. RC 03(E)/2025/CBI/BSFB/BLR on November 19, 2025 against Vivimed Labs Limited and four of its directors. The company's CFO and Company Secretary received a notice dated January 27, 2026 from CBI's Banking Securities Fraud Branch, Bengaluru on January 29, 2026.

High Court Intervention and Stay Order

Following the CBI's search and seizure operations, Vivimed Labs approached the High Court for the state of Telangana at Hyderabad seeking relief. The court granted comprehensive interim protection through its order dated February 06, 2026, which the company received on February 09, 2026.

The High Court's interim stay order provides extensive protection by:

• Restraining all further proceedings pursuant to the search and seizure operations
• Preventing coercive steps against Vivimed Labs Limited and its directors
• Blocking State Bank of India's declaration of the company's account as 'fraud'
• Maintaining status quo until further orders from the High Court

Regulatory Compliance and Disclosure

Vivimed Labs has maintained transparency through multiple disclosures under SEBI Listing Regulations. The company filed corporate announcements on February 03, 2026 and February 09, 2026, describing these disclosures as being made "in terms of good corporate practice."

The company has stated it remains in full compliance with SEBI Listing Obligations and Disclosure Requirements, 2015 and all applicable circulars. The interim stay order provides crucial breathing space for Vivimed Labs as it navigates the legal proceedings while maintaining its operational activities.

Vivimed Labs Limited has officially postponed its board meeting that was scheduled to take place on February 13, 2026, for the approval of its third quarter FY 2026 financial results. The pharmaceutical company communicated this development to both the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) through a formal notice dated February 11, 2026.

Meeting Postponement Details

The company's communication, signed by Company Secretary Yugandhar Kopparthi, informed the stock exchanges about the postponement without specifying the reasons for the delay. The original meeting was intended to approve the financial results for the third quarter of FY 2026.

Regulatory Compliance and Trading Window

Vivimed Labs has assured that it will intimate the revised date for the board meeting to the stock exchanges in due course. In compliance with regulatory requirements, the company has confirmed that the trading window for dealing in its securities will remain closed for designated persons until 48 hours after the declaration of the financial results following the rescheduled meeting.

Stock Exchange Information

The company trades on both major Indian stock exchanges with BSE code 532660 and NSE symbol VIVIMEDLAB. The formal communication was addressed to both exchanges as part of the mandatory disclosure requirements for listed companies.

Company Background

Vivimed Labs Limited operates with its registered office located at Kolhar Industrial Area, Bidar, Karnataka, and maintains its corporate office in Hyderabad, Telangana. The company is incorporated under CIN L02411KA1988PLC009465 and has been a listed entity on Indian stock exchanges.